CompletedNCT00224822
Aripiprazole for metabolic syndrome linked to other antipsychotic medicines
About this title
Read the official source — NCT00224822Medication studyAges 18–65United StatesSchizophrenia
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- AlbuquerqueSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateMarch 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 27
- Sponsor
- New Mexico VA Healthcare System
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00224822
- Official title
Show the full official title
The Effects of Aripiprazole on Patients With "Metabolic Syndrome": An Open-Label Trial
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Albuquerque
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is New Mexico VA Healthcare System.
Did this study involve medication?
Yes. The study involved medication, including Aripiprazole.
Who was this study for?
Listed age limits: 18 years to 65 years.
